We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.47%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$563M
AUM Growth
+$59.4M
Cap. Flow
+$52M
Cap. Flow %
9.23%
Top 10 Hldgs %
30.6%
Holding
102
New
10
Increased
33
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$14.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
BIIB icon
Biogen
BIIB
+$11.1M
4
CELG
Celgene Corp
CELG
+$8.17M
5
ENDP
Endo International plc
ENDP
+$7.77M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$11.1M
2
STJ
St Jude Medical
STJ
+$9.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$6.07M
4
PRGO icon
Perrigo
PRGO
+$4.25M
5
LH icon
Labcorp
LH
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
51
DexCom
DXCM
$32B
$4.36M 0.77%
220,000
-80,000
-27% -$1.36M
ABBV icon
52
AbbVie
ABBV
$435B
$4.33M 0.77%
70,000
-60,000
-46% -$3.66M
COO icon
53
Cooper Companies
COO
$14.5B
$4.29M 0.76%
100,000
-60,000
-38% -$2.4M
XNCR icon
54
Xencor
XNCR
$1.55B
$4.27M 0.76%
225,000
+25,000
+13% +$343K
BHC icon
55
Bausch Health
BHC
$2.34B
$4.23M 0.75%
210,000
+160,000
+320% +$4.53M
NVRO
56
DELISTED
NEVRO CORP.
NVRO
$4M 0.71%
54,300
+34,300
+172% +$2.33M
MGNX icon
57
MacroGenics
MGNX
$257M
$3.78M 0.67%
140,000
+20,000
+17% +$451K
RDUS
58
DELISTED
Radius Health, Inc.
RDUS
$3.67M 0.65%
100,000
-5,000
-5% -$177K
LIVN icon
59
LivaNova
LIVN
$4.2B
$3.52M 0.62%
70,000
– –
KITE
60
DELISTED
Kite Pharma, Inc.
KITE
$3.5M 0.62%
+70,000
New +$3.44M
ABT icon
61
Abbott
ABT
$187B
$3.31M 0.59%
+84,100
New +$3.35M
NXTM
62
DELISTED
NxStage Medical Inc.
NXTM
$3.15M 0.56%
+145,300
New +$2.59M
RVNC
63
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.99M 0.53%
220,000
+50,000
+29% +$884K
KERX
64
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.98M 0.53%
450,111
-499,889
-53% -$2.79M
CEMP
65
DELISTED
Cempra, Inc.
CEMP
$2.82M 0.5%
171,000
– –
BDX icon
66
Becton Dickinson
BDX
$48.2B
$2.54M 0.45%
15,375
-10,250
-40% -$1.64M
PODD icon
67
Insulet
PODD
$9.79B
$2.48M 0.44%
82,000
– –
PTLA
68
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.48M 0.44%
105,000
– –
NDRM
69
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.35M 0.42%
+144,546
New +$2.43M
CHRS icon
70
Coherus Oncology
CHRS
$196M
$2.22M 0.39%
+131,357
New +$2.47M
DVAX
71
DELISTED
Dynavax Technologies
DVAX
$2.19M 0.39%
150,000
– –
CMRX
72
DELISTED
Chimerix, Inc.
CMRX
$2.16M 0.38%
550,000
+50,000
+10% +$247K
HALO icon
73
Halozyme
HALO
$12.2B
$2.16M 0.38%
250,000
-181,000
-42% -$1.79M
CYH icon
74
Community Health Systems
CYH
$423M
$2.11M 0.37%
175,000
-97,250
-36% -$1.42M
ACHN
75
DELISTED
Achillion Pharmaceuticals
ACHN
$2.08M 0.37%
266,000
– –
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Rhenman & Partners Asset Management held 102 positions worth $563M, up 12% from $504M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $52M of net new capital in Q2 2016, opening 10 new positions and adding to 33 existing holdings. Its largest new stake was Pediatrix Medical: 80,000 shares worth $5.79M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Alkermes, an estimated $11.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2016 buy was Pediatrix Medical: 80,000 shares worth $5.79M.
  • Rhenman & Partners Asset Management added most to Alexion Pharmaceuticals in Q2 2016, an estimated $14.5M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2016 reduction was Alkermes, cutting an estimated $11.1M.
  • Rhenman & Partners Asset Management fully exited St Jude Medical in Q2 2016, selling an estimated $9.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $563M portfolio in Q2 2016.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q2 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $563M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2016, filed 1 Aug 2016.